ARIDIS_LOGO.png
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
03. November 2023 16:15 ET | Aridis Pharmaceuticals, Inc.
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) --...
respirerx.jpg
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
01. Februar 2023 08:30 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
ARIDIS_LOGO.png
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
30. November 2022 07:00 ET | Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury
29. November 2021 08:45 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
respirerx.jpg
RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference
08. Juni 2021 18:20 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury
12. Mai 2021 09:15 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...